We have got a piece of good news about Corona Virus Fight Scientists have found a COVID-19 Drug which can kill the virus in 48 hours, its anti-parasite drug.
While shown to work in the lab environment, Ivermectin cannot be utilized in humans for COVID-19 until additional testing and clinical trials have been completed to validate the effectiveness of the drug at levels safe for human dosing.
For any medical questions you have regarding your health, please consult with your healthcare provider.
COVID-19 Drug which can kill the virus in 48 hours
The possible utilization of Ivermectin to combat COVID-19 remains unproven and depends on pre-clinical testing and clinical trials to progress the job.
A Monash University-led research has proven that an anti-parasitic drug already available around the world can”kill” the virus within two days in cell culture.
Scientists showed that a single dose of this drug, Ivermectin, could halt the SARS-CoV-2 virus growth in cell culture.
The upcoming steps are to ascertain the right human dosage — ensuring the doses shown to effectively deal with the virus in vitro are safe for people.
The use of Ivermectin to fight COVID-19 is dependent upon pre-clinical testing and clinical trials, even together with financing urgently required to progress the work.
Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro from a wide range of viruses including HIV, Dengue, Influenza and Zika virus.
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic medication already available around the world kills the virus within two days.
The Monash Biomedicine Discovery Institute’s Dr. Kylie Wagstaff, who led the study, said the scientists revealed that the drug, Ivermectin, ceased the SARS-CoV-2 virus growing in cell culture within 48 hours.
“We discovered that even one dose could basically remove all viral RNA by two days and even at 24 hours there was a very significant decrease in it,” Dr. Wagstaff said.
Ivermectin is an FDA-approved anti-parasitic medication that has also been shown to be effective from vitro from a broad selection of viruses such as HIV, Dengue, Influenza and Zika virus.
Dr. Wagstaff cautioned the evaluations conducted in the study were at vitro and that trials necessary to be completed in people.
“Ivermectin is very widely used and viewed as a safe medication. We will need to figure out now whether the dose you can use it at in humans will succeed — that is the next step,” Dr. Wagstaff stated.
“Sometimes when we’re using a global pandemic and there is not an approved treatment if we had a compound that was available around the world then which may help people sooner. It’s going to be a while before a vaccine is available.
Even though the mechanism whereby Ivermectin operates on the virus is not known, it’s possible, based on its activity in other viruses, that it functions to stop the virus’ dampening down’ the host cells’ ability to clean it, Dr. Wagstaff said.
Royal Melbourne Hospital’s Dr. Leon Caly, a Senior Medical Scientist at the Victorian Infectious Diseases Reference Laboratory (VIDRL) in the Doherty Institute in which the experiments with live coronavirus have been ran, is the study’s first author.
“Since the virologist who was a part of the group who had been first to isolate and discuss SARS-COV2 outside of China at January 2020, I am excited about the prospect of Ivermectin being used as a possible drug against COVID-19,” Dr. Caly said.
Dr. Wagstaff made a preceding breakthrough finding on Ivermectin at 2012 when she identified the drug as well as its own antiviral activity with Monash Biomedicine Discovery Institute’s Professor David Jans, also an author on this paper. Professor Jans and his staff have been researching Ivermectin for 10 or more years.
Dr. Wagstaff and Professor Jans started investigating whether it worked on the SARS-CoV-2 virus as soon as the pandemic was understood to have begun.
Using Ivermectin to combat COVID-19 would depend on the results of further pre-clinical testing and finally clinical trials, together with funding desperately required to keep progressing the job, Dr. Wagstaff said.
Reference:”The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 at vitro” by Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans and Kylie M. Wagstaff, 3 April 2020, Antiviral Research.